dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Espinosa Pereiro, Juan |
dc.contributor.author | Ghimire, Samiksha |
dc.contributor.author | Sturkenboom, Marieke G.G. |
dc.contributor.author | Alffenaar, Jan-Willem |
dc.contributor.author | Tavares, Margarida |
dc.contributor.author | Aguirre García, Sarita Katerinne |
dc.contributor.author | Tórtola Fernández, Mª Teresa |
dc.contributor.author | Sánchez Montalvá, Adrián |
dc.date.accessioned | 2023-03-01T11:25:51Z |
dc.date.available | 2023-03-01T11:25:51Z |
dc.date.issued | 2022-12-20 |
dc.identifier.citation | Espinosa-Pereiro J, Ghimire S, Sturkenboom MGG, Alffenaar JWC, Tavares M, Aguirre S, et al. Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial. Pharmaceutics. 2022 Dec 20;15(1):9. |
dc.identifier.issn | 1999-4923 |
dc.identifier.uri | https://hdl.handle.net/11351/9078 |
dc.description | Rifampicina; Tuberculosi; Població vulnerable |
dc.description.sponsorship | This study is part of the European South American TB Research Collaborative Network (EUSAT-RCS), a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 823890. A.S.M. is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Pharmaceutics;15(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tuberculosi - Tractament |
dc.subject | Medicaments antibacterians - Ús terapèutic |
dc.subject.mesh | Tuberculosis |
dc.subject.mesh | Anti-Bacterial Agents |
dc.subject.mesh | /therapeutic use |
dc.title | Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/pharmaceutics15010009 |
dc.subject.decs | tuberculosis |
dc.subject.decs | antibacterianos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.3390/pharmaceutics15010009 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Espinosa-Pereiro J] Unitat de Medicina Tropical i Salut Internacional Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Ghimire S, Sturkenboom MGG] Department Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Alffenaar JC] Department Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Westmead Hospital, Sydney, Australia. Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, Australia. [Tavares M] Infectious Diseases Service, Centro Hospitalar de São João, Porto, Portugal. [Aguirre S] National Program for Tuberculosis, Ministry of Health, Asunción, Paraguay. [Tórtola T] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Sanchez-Montalva A] Unitat de Medicina Tropical i Salut Internacional Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Grupo de Estudio de Infecciones por Micobacterias, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GEIM-SEIMC), Madrid, Spain |
dc.identifier.pmid | 36678638 |
dc.identifier.wos | 000918283300001 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/823890 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |